ANI Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Rare Disease assets now drive 60% of revenue, with Cortrophin and ILUVIEN showing strong growth and long-term durability due to large underpenetrated markets and patent protection. Generics and Brands provide cash flow for reinvestment, while expanded sales teams and strategic initiatives support continued momentum.
-
Strong 2025 results and robust 2026 guidance highlight rare disease as the main growth driver, with Cortrophin Gel expansion and a new sales force targeting acute gouty arthritis. ILUVIEN's growth is supported by new data and label expansion, while operating leverage is expected in 2027.
-
The company projects over $1 billion in 2026 sales, with rare disease driving 60% of revenue and Cortrophin Gel as the lead growth asset. Generics continue to deliver strong cash flow, funding expansion and clinical initiatives, while financial strength supports ongoing transformation.
-
Rare disease is set to drive over 60% of 2026 revenues, led by Purified Cortrophin Gel’s 55%-65% growth and a major expansion into acute gouty arthritis. Generics remain a strong cash generator, funding rare disease investments, while Iluvien’s growth is targeted through new commercial strategies and access initiatives.
Fiscal Year 2025
-
Record 2025 results with 44% revenue growth and 47% adjusted EBITDA growth, led by rare disease and generics. 2026 guidance targets over $1B in revenue, with Cortrophin Gel and generics as key drivers and significant investments in sales force expansion and clinical evidence generation.
-
Rare disease and generics drive strong growth, with 2025 revenue and EBITDA guidance up over 39% and 42% respectively. Cortrophin Gel sees broad uptake, especially in new indications and via prefilled syringes, while ILUVIEN and generics benefit from focused commercial and R&D strategies.
-
The business is experiencing strong growth driven by rare disease assets, especially Cortrophin Gel, which targets large, underpenetrated patient populations. Expanded Salesforce, clinical evidence, and new product formats are fueling adoption, while ILUVIEN is positioned for growth after a reset year.
-
Record Q3 results with 54% revenue growth and nearly doubled Cortrophin Gel sales. 2025 guidance raised for revenue, EBITDA, and EPS, with Rare Disease and Generics driving performance. ILUVIEN faces near-term headwinds but long-term growth expected.
-
Rare disease therapeutics, especially Cortrosyn, are driving strong revenue and EBITDA growth, with significant expansion in generics and brands supporting further investment. The company is well-positioned against tariff risks, focusing capital on rare disease asset acquisitions and organic growth, while new product launches and clinical initiatives underpin a robust multi-year outlook.
-
Rare disease therapeutics drive robust growth, with Purified Cortrophin Gel and ILUVIEN leading revenue expansion and new product launches. Financial guidance projects strong double-digit growth, supported by operational excellence in generics and U.S.-based manufacturing.
-
Record Q2 results with 53% revenue growth, driven by rare disease and generics. 2025 guidance raised for revenue, EBITDA, and EPS, with Purified Cortrophin Gel leading growth. Retina guidance lowered due to Medicare access issues, while generics and brands remain strong.
-
The New Day trial showed Iluvien as a long-acting corticosteroid implant for early DME reduced injection burden and achieved non-inferior visual outcomes compared to aflibercept, with a manageable safety profile. Results support earlier use in DME, especially for anti-VEGF non-responders, and may expand Iluvien's market reach.
-
Rare disease, generics, and brands drive strong growth, with rare disease as the primary engine. 2025 guidance was raised twice, reflecting robust momentum in Cortrophin Gel and generics. Sales force expansion and product innovation support multi-year growth across all business units.
-
Rare disease assets are set to drive nearly half of 2025 revenues, with strong growth in both rare disease and generics segments. Recent M&A expanded the portfolio, and new product launches and operational excellence support robust financial guidance for 2025.
-
Record Q1 revenue and profit growth led to raised 2025 guidance, with strong generics and rare disease performance. Retina products faced U.S. access challenges but are recovering, and new launches plus strategic investments support multi-year growth.
-
Rare disease and ophthalmology drive growth, with 2025 revenue guided at $756–$776 million. ILUVIEN and Yutiq expand the rare disease portfolio, targeting underpenetrated DME and NIUPS markets, with key clinical trials and a sales force expansion supporting future growth.
-
Guidance for 2025 was raised due to strong rare disease and generics performance, with Purified Cortrophin Gel and the ILUVIEN/YUTIQ franchise driving growth. The company is leveraging a virtuous cycle between its three business segments and aims to expand its rare disease focus over time.
-
Rare disease is set to drive nearly half of 2025 revenues, led by Cortrophin Gel and the Alimera acquisition, while generics and brands continue to deliver strong growth and cash flow. Market expansion, new product launches, and operational synergies underpin the strategy, with further M&A considered opportunistically.
-
Rare Disease is the primary growth engine, led by Cortrophin Gel and expanded by the Alimera acquisition, which added ILUVIEN and YUTIQ. The ACTH market has returned to growth, and new product launches and high barriers to genericization support a strong outlook. 2025 guidance projects $739–$759 million in sales.
-
Rare disease therapeutics drove strong 2024 growth, led by Purified Cortrophin Gel and expanded by the Alimera acquisition. 2025 guidance projects 24–27% revenue growth, with new product launches, clinical studies, and commercial investments supporting continued momentum.
Fiscal Year 2024
-
Record Q4 and 2024 results led to raised 2025 guidance, with rare disease and generics driving growth. Cortrophin Gel and new ophthalmology assets outperformed, while operational investments and market access challenges shape near-term outlook.
-
The business has shifted to a rare disease focus, with Cortrophin, ILUVIEN, and YUTIQ driving growth. Clinical trials like NEW DAY and SYNCHRONICITY could expand market opportunities, while commercial synergies and strong IP protection support a durable, multi-asset portfolio.
-
Rare Disease therapeutics are set to drive over half of 2025 revenues, with Cortrophin Gel and new ophthalmology assets fueling multi-year growth. The Alimera acquisition expands the portfolio and sales reach, while generics and manufacturing continue to deliver strong results.
-
Strong quarterly sales were driven by Rare Disease growth, especially Cortrophin Gel, and the integration of Alimera Sciences' ophthalmology assets. Generics continued to grow with new launches, while established brands provided cash flow. Rare Disease expansion and business development remain top priorities.
-
Q3 2024 saw record revenue growth, driven by rare disease and generics, and the successful Alimera acquisition. Full-year guidance was raised across all key metrics, with Cortropin Gel and new ophthalmology assets expected to drive future growth.
-
Record Q2 revenue growth was driven by rare disease and generics, prompting raised 2024 guidance for revenue, EBITDA, and EPS. The pending Alimera acquisition will expand the rare disease portfolio and global reach, while new product launches and manufacturing expansion support future growth.
-
The acquisition adds two high-growth ophthalmology assets, expanding the rare disease business and global reach. Financial terms include $381M upfront and up to $29M in CVRs, with $10M in cost synergies expected. Management anticipates robust growth, high margins, and substantial shareholder value creation.
-
Strong growth continues, led by rare disease and generics, with 2024 revenue guidance of $520–$542 million. Purified Cortrophin Gel drives rare disease expansion, while U.S.-based manufacturing and R&D excellence support generics growth.